Aura Biosciences, Inc. (NASDAQ:AURA) Given Average Rating of “Buy” by Analysts

Aura Biosciences, Inc. (NASDAQ:AURA) has received an average rating of “Buy” from the seven research firms that are currently covering the stock, MarketBeat.com reports. Five analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $23.00.

AURA has been the subject of several recent analyst reports. Lifesci Capital raised Aura Biosciences to a “strong-buy” rating in a research note on Friday, January 31st. HC Wainwright reissued a “buy” rating and issued a $22.00 price target on shares of Aura Biosciences in a research note on Thursday, November 14th.

Insider Activity

In other news, insider Los Pinos Elisabet De sold 15,955 shares of the company’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $7.67, for a total value of $122,374.85. Following the completion of the sale, the insider now owns 304,692 shares in the company, valued at $2,336,987.64. This represents a 4.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders sold a total of 23,045 shares of company stock worth $177,242 over the last 90 days. 5.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Aura Biosciences

Several hedge funds have recently modified their holdings of AURA. Long Focus Capital Management LLC lifted its holdings in shares of Aura Biosciences by 123.9% during the fourth quarter. Long Focus Capital Management LLC now owns 2,537,774 shares of the company’s stock valued at $20,861,000 after purchasing an additional 1,404,228 shares during the last quarter. Levin Capital Strategies L.P. lifted its holdings in shares of Aura Biosciences by 169.1% during the fourth quarter. Levin Capital Strategies L.P. now owns 1,247,619 shares of the company’s stock valued at $10,255,000 after purchasing an additional 783,984 shares during the last quarter. B Group Inc. purchased a new stake in shares of Aura Biosciences during the fourth quarter valued at $3,885,000. Franklin Resources Inc. lifted its holdings in shares of Aura Biosciences by 14.8% during the third quarter. Franklin Resources Inc. now owns 1,668,960 shares of the company’s stock valued at $15,571,000 after purchasing an additional 215,597 shares during the last quarter. Finally, Ensign Peak Advisors Inc lifted its holdings in shares of Aura Biosciences by 43.3% during the fourth quarter. Ensign Peak Advisors Inc now owns 390,695 shares of the company’s stock valued at $3,212,000 after purchasing an additional 118,000 shares during the last quarter. 96.75% of the stock is owned by hedge funds and other institutional investors.

Aura Biosciences Stock Performance

NASDAQ:AURA opened at $7.37 on Thursday. Aura Biosciences has a 1 year low of $6.63 and a 1 year high of $12.38. The stock has a market cap of $368.13 million, a price-to-earnings ratio of -4.26 and a beta of 0.29. The business has a fifty day moving average of $7.96 and a 200-day moving average of $8.72.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.